复杂腹主动脉与胸腹主动脉瘤医师改良开窗分支腔内修复术后衰弱动态变化及其对早期临床结局影响的前瞻性评估
单中心前瞻性医师发起研究纳入70例接受医师改良开窗分支腔内修复术的复杂腹主动脉与胸腹主动脉瘤患者,采用Hopkins衰弱评分和衰弱指数评估衰弱、L3总腰大肌面积评估肌少症,发现术前衰弱与肌少症与早期并发症相关,术后1个月衰弱与肌少症加重、6个月恢复至基线附近。
要点
- 术前Hopkins衰弱评分非衰弱患者早期并发症发生率更低(P = .033)。
- 发生早期并发症患者基线L3总腰大肌面积显著更低(P = .016)。
- 术后1个月衰弱评分与肌少症显著加重,6个月恢复至基线附近。
核心结论
- 术前衰弱与肌少症与医师改良开窗分支腔内修复术后早期并发症相关。
- 术后1个月患者衰弱与肌少症加重,6个月时从初始下降中恢复,提示衰弱与肌少症是可逆过程而非持续下降的单向现象。
研究设计与样本
- 单中心前瞻性医师发起研究性器械豁免方案(FDA# G200159)连续纳入患者,研究时间为2021年2月9日至2023年6月2日,共分析70例。
- 采用Hopkins衰弱评分和衰弱指数评估衰弱,L3总腰大肌面积评估肌少症,随访期重复测量。
- 随访Hopkins衰弱评分与衰弱指数采用Wilcoxon符号秩检验与基线比较,随访腰大肌面积采用配对t检验与基线比较,基线衰弱与并发症关联采用Wilcoxon秩和检验。
主要发现
- 基线时Hopkins衰弱评分将54%患者判为非衰弱、43%为中度衰弱、3%为衰弱。
- 医师改良开窗分支腔内修复术技术成功率为94%,院内死亡1例,早期主要不良事件见于10例(14.3%)患者。
- 发生早期并发症与未发生早期并发症患者基线衰弱指数无差异;Hopkins衰弱评分非衰弱患者早期并发症发生率更低(P = .033)。
- 发生早期并发症患者基线L3总腰大肌面积显著更低(P = .016)。
- 术后1个月Hopkins衰弱评分及其分类显著升高(P = .001和P = .01),肌少症显著加重(平均腰大肌面积变化:-96 mm2,P = .005);术后6个月Hopkins衰弱评分、分类及腰大肌面积恢复至基线附近(P = .42、P = .38,平均腰大肌面积变化:+4 mm2,P = .6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Frailty, a predictor of poor outcomes, has been widely studied as a screening tool in surgical decision-making. However, the impact of frailty on the outcomes after fenestrated-branched endovascular aortic repairs (FBEVARs) is less well established. In addition, the changes in frailty during recovery after FBEVAR are unknown. We aim to assess the impact of frailty on outcomes of high-risk patients undergoing physician-modified FBEVARs for complex abdominal and thoracoabdominal aortic aneurysms, as well as the changes in frailty during follow-up. METHODS: Consecutive patients enrolled in a single-center prospective Physician-Sponsored Investigational Device Exemption protocol (FDA# G200159) were evaluated. In addition to the baseline characteristics, frailty was assessed using the Hopkins Frailty Score (HFS) and frailty index (FI) measured by the Frailty Meter. Sarcopenia was measured by L3 total psoas muscle area (PMA). These measurements were repeated during follow-up. The follow-up HFS and FI were compared with baseline scores using the Wilcoxon signed-rank test, whereas follow-up PMA measurements were compared with the baseline using the paired t test. The association between baseline frailty and morbidity was evaluated by the Wilcoxon rank-sum test. RESULTS: Seventy patients were analyzed in a prospective Physician-Sponsored Investigational Device Exemption study from February 9, 2021, to June 2, 2023. At baseline, HFS identified 54% of patients as not frail, 43% as intermediately frail, and 3% as frail. Technical success of FBEVAR was 94% with one in-hospital mortality. Early major adverse events were seen in 10 (14.3%) patients. No difference in baseline FI was seen between patients with early morbidity and those without. Patients who were not frail per HFS were less likely to experience early morbidity (P = .033), and there was a significantly lower baseline PMA in patients who experienced early morbidity (P = .016). At 1 month, patients experienced a significant increase in HFS and HFS category (P = .001 and P = .01) and a significant decrease in sarcopenia (mean PMA: -96 mm2, P = .005). At 6 months, HFS and HFS category as well as PMA returned toward baseline (P = .42, P = .38, and mean PMA: +4 mm2, P = .6). CONCLUSIONS: Preoperative frailty and sarcopenia were associated with early morbidity after physician-modified FBEVAR. During follow-up, patients became more frail and sarcopenic by 1 month. Recovery from this initial decline was seen by 6 months, suggesting that frailty and sarcopenia are reversible processes rather than a unidirectional phenomenon of continued decline.
引用
- Pyun AJ, Ding L, Hong YH, et al. Prospective assessment of dynamic changes in frailty and its impact on early clinical outcomes following physician-modified fenestrated-branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2023. PMID: 37923022. doi:10.1016/j.jvs.2023.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。